Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
LEGN Stock Chart & Stats
$30.29
-$0.50(-1.49%)
At close: 4:00 PM EST
$30.29
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$27.34 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)1.40M
Market Cap
$5.59B
Enterprise Value$5.44B
Total Cash (Recent Filing)$992.59M
Total Debt (Recent Filing)$410.24M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Mar 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding184,570,710
10 Day Avg. Volume1,417,418
30 Day Avg. Volume1,396,163
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.86
Price to Sales (P/S)4.74
P/FCF Ratio-18.81
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue5.98
Enterprise Value/Gross Profit12.59
Enterprise Value/Ebitda-28.98
Forecast
1Y Price Target
$73.75Price Target Upside143.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.77
Revenue Forecast (FY)$1.03B
Bulls Say, Bears Say
Bulls Say
Commercial ManufacturingCommercial manufacturing advanced with Tech Lane in Belgium now producing commercial batches, and the Raritan expansion is on track for approval by year-end.
Financial PerformanceLegend Biotech Corporation achieved an OS label update and expanded its capacity, with over 9,000 patients treated, up from over 7,500.
Market DemandLegend confirmed that manufacturing capacity now meets market demand, eliminating prior patient wait times.
Bears Say
Competitive LandscapeBispecific growth validates demand but might temper 2L CAR-T use, potentially creating competitive headwinds for CARVYKTI.
Investor SentimentStock reaction remains muted despite steady beats, underscoring investor fatigue with incremental beats and a preference for step-function evidence of early-line acceleration.
Safety ConcernsCarvykti label updated to include new safety warnings, including immune effector cell-associated enterocolitis as a black-boxed warning.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $27.34 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $5.59B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Mar 18, 2026 which is in 120 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Nov 12, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.073 by $0.023.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 184,570,710 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.073. Following the earnings report the stock price went down -2.654%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
Legend Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.75 (143.48% Upside)
$73.75 (143.48% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.06%
12-Months-Change
Fundamentals
Return on Equity
-22.60%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
LEGN Company Deck
LEGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a largely positive outlook driven by significant sales growth of CARVYKTI, successful international expansion, and advancements in clinical trials and manufacturing capacity. However, challenges like managing neurotoxicity and achieving profitability remain.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$73.75
▲(143.48% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
―
Insiders
16.01% Mutual Funds
17.47% Other Institutional Investors
63.81% Public Companies and
Individual Investors